Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Halozyme Therapeutics Inc. ($HALO) stock perked up as the company announced the updated results from the Phase 2 HALO-202 study assessing its lead product candidate PEGPH20, combined with Celgene's ABRAXANE (nab-paclitaxel) and gemcitabine (AG), in patients with advanced pancreatic cancer showed a treatment benefit. In patients showing high levels of a biomarker called hyaluronan (HA), the objective response rate was 45% compared to 31% in patients treated with AG alone. The company is currently carrying out a Phase 3 study, HALO-301, evaluating PEGPH20 and AG in a first-line setting in patients with metastatic pancreatic cancer.
The company stock has gained over 31 percent in the past 12 months while its Year to Date gain stands at 28 percent.

Eli Lilly ($LLY) announced the results from the Phase 3 MONARCH 2 study assessing the combination of its abemaciclib and fulvestrant on patients with treatment-resistant HR+/HER2- breast cancer. The study showed that the patients  experienced a statistically significant improvement in progression-free survival (PFS) compared to those treated with fulvestrant alone. The most frequent grade 3 (serious) abemaciclib-related adverse events were neutropenia (23.6%) and diarrhea (13.4%) while median PFS in the abemaciclib cohort was 16.4 months versus 9.3 months in the fulvestrant monotherapy group.
The company stock has gained over 28 percent this year so far while its 12 months gain stands at 31 percent.

 

Amgen ($AMGN) announced positive results from Phase 2 as  '264 clinical trial in metastatic melanoma patients showed treatment with IMLYGIC and Bristol-Myers Squibb's YERVOY delivered a statistically significantly greater response rate than YERVOY alone. 38% of patients receiving the combination responded compared to 18% who received YERVOY as monotherapy.

Pfizer ($PFE) announced positive data for the  trial of talazoparib. The Phase 2 data showed that its investigational, dual-mechanism poly ADP ribose polymerase inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive advanced breast cancer.

Puma Biotechnology ($PBYI) announced the positive  results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The trial is being performed by the TBCRC and enrolled three cohorts of patients.

Exact Sciences ($EXAS) initiated a Class 2 recall of its Sample Mixer v2 Upgrade units that are used with the Cologuard. The company has taken this action because of instances of door damage when the Sample Holder opens during a run and the lid makes contact with the Sample Mixer door.

 

Bristol Myers Squibb ($BMY) announced inking a new agreement with Qiagen ($QGEN) for the purpose of developing gene expression profiles (GEPs) as predictive/prognostic tools for use with BMY's immuno-oncology (I-O) therapies. The terms of the initial agreement provides for the companies to develop GEPs for several BMY I-O candidates.

Novo Nordisk ($NVO) announced inking an agreement with Innate Pharmaceuticals for  exclusive global rights to IPH5401, a clinical-stage anti-C5aR antibody for treating a range of cancers. After the issuance of the shares, Novo Nordisk will own as much as 15.8% of Innate. Currently, it has 10.3 percent stake in the company.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
JPMorgan Chase & Co.
Reiterates
Apple (AAPL)
Overweight
$165.00
High
Longbow Research
Reiterates
Apple (AAPL)
Buy

Medium
Guggenheim
Reiterates
Apple (AAPL)
Buy
$180.00
High
Jefferies Group LLC
Reiterates
Analytica Bio - Energy Corp (ABEC)
Buy

Low
Jefferies Group LLC
Reiterates
Analytica Bio - Energy Corp (ABEC)
Buy

Low
Jefferies Group LLC
Reiterates
Abeona Therapeutics (ABEO)
Buy
$11.00
High
Barclays PLC
Reiterates
Barrick Gold Corp (ABX)
Equal Weight
$22.00 -> $20.00
Low
Jefferies Group LLC
Set Price Target
Acadia Healthcare Company (ACHC)
Buy
$55.00
Low

Gainers (% price change)
Last Trade
Change
Mkt Cap
Achillion Pharmaceuticals
ACHN
5.03
+0.52 (11.53%)
696.99M
Codexis, Inc.
CDXS
4.45
+0.45 (11.25%)
214.36M
Synergy Pharmaceuticals
SGYP
4.00
+0.37 (10.19%)
930.56M
Cooper Companies Inc
COO
238.32
+18.53 (8.43%)
11.72B
BioScrip Inc
BIOS
2.05
+0.13 (6.77%)
263.09M
Losers (% price change)

Community Health Systems
CYH
8.78
-0.39 (-4.25%)
1.04B
Simulations Plus, Inc.
SLP
12.60
-0.35 (-2.70%)
230.59M
Compugen Ltd. (USA)
CGEN
4.65
-0.10 (-2.11%)
232.16M
SciClone Pharmaceuticals
SCLN
9.65
-0.20 (-2.03%)
517.61M
Clearfield Inc
CLFD
13.00
-0.25 (-1.89%)
183.22M
Most Actives (dollar volume)

Johnson & Johnson
JNJ
130.08
+1.30 (1.01%)
351.86B
Regeneron Pharmaceuticals
REGN
480.43
+14.41 (3.09%)
51.84B
Pfizer Inc.
PFE
32.54
-0.17 (-0.52%)
194.14B
Amgen, Inc.
AMGN
159.15
+2.91 (1.86%)
117.79B
Celgene Corporation
CELG
118.73
+2.32 (1.99%)
94.33B